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Background: Fabry’s disease is a rare X-linked, hereditary lysosomal storage disease caused by a deficiency of the
enzyme α-galactosidase A. Granulomatosis with polyangiitis is characterized by the involvement of the respiratory
tract and kidneys. Here, we report the first case of the coexistence of these diseases.
Case presentation: We describe a 29-year-old man suffering from fever with maxillary sinusitis, multiple lung
nodules, and proteinuria. He was diagnosed with Fabry’s disease accompanying granulomatosis with polyangiitis
on the basis of the low activity of peripheral leukocyte α-galactosidase A and pathological findings in the lung
and kidney. Glucocorticoid and cyclophosphamide were administered, followed by enzyme replacement therapy.
Progression to end-stage renal disease has not been observed for 6 years until the time of drafting this manuscript.
Conclusion: Because both Fabry’s disease and granulomatosis with polyangiitis or crescentic glomerulonephritis are
rare diseases, their concurrence in this and related cases suggests there may be a pathogenic link between these
two conditions. Fabry’s disease may be underdiagnosed, particularly in cases of granulomatosis with polyangiitis or
crescentic glomerulonephritis.
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Fabry’s disease is a rare X-linked, hereditary lysosomal
storage disease caused by the deficiency of the enzyme
α-galactosidase A (αGL-A). This deficiency results in the
accumulation of the neutral glycosphingolipid globo-
triaosylceramide (GL-3) in multiple organs [1]. It causes
a multisystem condition characterized by reddish-purple
maculopapular lesions on the skin (angiokeratoma corporis
diffusum), corneal opacities (cornea verticillata) hypohi-
drosis, gastroenteritis, chronic airflow obstruction, left
ventricular hypertrophy, and early-onset of stroke. With
advanced age, the progressive lysosomal GL-3 accumula-
tion leads to renal failure due to the dysfunction of
interstitial tubules, epithelial cells, and mesangial cells
[2]. Therefore, early diagnosis of Fabry’s disease is im-
portant for successful therapeutic intervention with* Correspondence: hhanaoka@a3.keio.jp
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unless otherwise stated.enzyme replacement therapy [3]. It’s diagnosis is made by
demonstrating a deficiency of αGL-A in a blood sample or
detection of a disease-causing mutation in the GLA gene.
Fabry’s disease is rare. Its incidence in the United Kingdom
is reported to be 0.3 per 100,000, according to the registry
of all cases found between 1980 and 1995 [4,5].
This report describes a rare case of Fabry’s disease with
granulomatosis with polyangiitis (GPA), which is a multi-
system inflammatory disease that affects the respiratory
tract and kidneys [6]. The prevalence of GPA has in-
creased in last 2 decades but it is still rare disease [7].
According to United Kingdom general practice research
database from 1990 to 2005, it is reported to be 0.8 per
100,000 [8]. In the present case, upper and lower respira-
tory tract involvement and pauci-immune necrotizing and
crescentic glomerulonephritis were pathologically con-
firmed. Glucocorticoids and oral cyclophosphamide were
administered, followed by enzyme replacement therapy.
Literature review found three additional cases of Fabry’s
disease complicated with crescentic glomerulonephritisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ulonephritis are rare diseases, there may be a pathogenic
link between these two conditions.
Case presentation
A 29-year-old man was admitted to our hospital on
September 22, 2007 with left maxillary sinus pain and a
1-month history of general malaise and fever. His past
medical history did not disclose any evidence of specific
diseases, including renal diseases. So he had not taken any
drugs before this admission. Family history revealed that
his father died of cerebral hemorrhage at the age of 45
and his mother had no cardiovascular or renal disease. He
has no sibling. At admission, the patient’s height was
174 cm, body weight was 79 kg, and his body temperature
was 38.2°C. Left maxillary sinus tenderness was observed
on physical examination, but no chest murmur or neuro-
logical findings were noted. A panel of laboratory studies re-
vealed the following results: serum creatinine (Cr) 0.9 mg/
dl, sodium 136.1 mEq/l, potassium 3.9 mEq/l, hemoglobin
15.1 g/dl, white blood cell count 17,600/μl, platelet count
180,000/μl, total serum proteins 6.7 g/dl, albumin 3.1 g/dl,
and C-reactive protein (CRP) 16.5 mg/dl. Although most
of these findings are unremarkable, the white blood cellFigure 1 Whole body computed tomography scan before treatmen
(b, c, d) Multiple lung nodules were identified (yellow arrows).count was marginally high, the albumin level was margin-
ally low, and the CRP level was substantially elevated.
Antinuclear antibody or myeloperoxidase-antineutrophil
cytoplasmic antibody (ANCA) was not detected, but
proteinase 3 (PR3)-ANCA was detected at a low titer
(24 enzyme-linked immunosorbant assay unit). Results
of negative serum test were obtained for Hepatitis C virus,
Hepatitis B surface, and core antigens. HLA-typing was
not done. Urinalysis revealed hematuria (51–100 red blood
cells per high-power field) and proteinuria (0.58 g/day).
Whole body computed tomography (CT) revealed left
maxillary sinusitis and multiple lung nodules (Figure 1).
Two-dimensional transthoracic echocardiography did not
reveal signs of left ventricular hypertrophy, with an inter-
ventricular septal thickness of 10 mm and left ventricular
posterior wall thickness of 10 mm. Left ventricular systolic
function was preserved (ejection fraction 58.9%). A CT-
guided needle biopsy of the lung showed a multinucleated
giant cells and inflammatory cell infiltrate in necrotizing le-
sions (Figure 2a), and a renal biopsy showed focal segmen-
tal necrotizing and crescentic glomerulonephritis with
interstitial granulomas. We could not find any multinucle-
ated giant cells in renal tissue (Figure 2b–d). The glomeru-
lar podocytes were swollen and vacuolated. A semi-thint. (a) The left nasal cavity was filled with soft tissue (pink arrow).
Figure 2 Lung biopsy performed by computed tomography-guided needle biopsy and renal biopsy before treatment. (a) Multi-nucleated
giant cells and inflammatory cells infiltrating necrotizing lesions are shown. (b) Granulomatous tubulointerstitial nephritis. Hematoxylin and eosin stain,
×40. (c) Focal segmental necrotizing glomerulonephritis (arrow). The glomerular podocytes were swollen and vacuolated. PASM stain, ×400.
(d) Crescentic glomerulonephritis. Podocytes in the cellular crescent were not vacuolated. PASM stain, ×400. (e) Inclusion bodies were
detected in the podocytes. Toluidine blue stain, ×400. (f) Podocytes containing osmiophilic inclusion bodies (“myeloid bodies”) were
revealed by electron microscopy (×2000).
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copy showed numerous inclusion bodies in the podocytes
(Figure 2e). Immunofluorescence revealed no IgG, IgA,
IgM, C3, or C1q deposition along the capillary wall. Elec-
tron microscopy revealed lamellated inclusion bodies
(“myeloid bodies”) in the podocytes (Figure 2f). Analysis
of the leukocytes demonstrated an αGL-A activity level of
11.8 nmol/h/mg (normal range: 49.6–116 nmol/h/mg).
After careful consideration of the findings, although this
patient lacked any other pathognomonic signs of Fabry’s
disease, such as acroparesthesias, dyshidrosis, or cutane-
ous angiokeratomas, a diagnosis of Fabry’s disease associ-
ated with GPA was made.
Treatment with prednisolone (PSL, 60 mg/day) and oral
cyclophosphamide (100 mg/day) was initiated on October
6, 2007. The patient received enzyme replacement therapy
in the form of agalsidase alfa at 0.2 mg/kg every other
week starting July 14, 2008. Complete resolution of theproteinuria, lung nodules, and maxillary sinusitis was seen
within 2 months of initiation of this therapy. Oral cyclo-
phosphamide was discontinued January 27, 2009, and
azathioprine (50 mg/day) was started for maintenance
therapy. The PSL dosage was gradually tapered to
9 mg/day by August 2009. At last follow-up on October
16, 2013, the patient’s Cr was 1.3 mg/dl.
Discussion
This is the first report of the coexistence of Fabry’s dis-
ease and GPA, although Fabry’s disease with necrotizing
crescentic glomerulonephritis has been reported in 3
cases previously [9,10]. We reviewed the three previous
cases and compared their findings with those of the
present case (Table 1). Interestingly, none of the previous
cases were diagnosed as Fabry’s disease before a diagnosis
of renal disease was made. Pauci-immune glomeruloneph-
ritis was confirmed in the present case and in the two
Table 1 Demographic and clinical features of patients with Fabry’s disease complicated by crescentic
glomerulonephritis
Singh et al. (5) Singh et al. (5) Shimazu et al. (6) This case
Age (years) 11 26 58 29
Gender M F F M
Chief complaint Fever, arthralgia Fever, pedal edema Hematuria, pedal edema Fever, sinus tenderness
BUN (mg/dl) 35 ND 42.3 14.4
Cr (mg/dl) 2.6 1.4 4.7 0.9
Proteinuria (g/day) 1.3 0.7 ND 0.6
PR3 ANCA Negative Negative Negative Positive
MPO ANCA Negative Negative Negative Negative
Anti-GBM antibody Negative Negative Negative Negative
ANA Negative Negative Negative Negative
Pauci-immune response Yes Yes No Yes
Diagnosis of GPA No No No Yes
αGL-A activity < 10%*1 50%* 76.1** 11.8***
Mutation in the αGL-A gene ND ND ND p.N224H/c.670A > C
Treatment PSL IVCY PSL CYC 150 mg/day PSL 60 mg/day HD PSL 60 mg/day CYC 100 mg/day
Follow-up period (months) 16 15 3 72
Final Cr level (mg/dl) 8.4 1.34 2.0–3.0 1.30
*1Percentage of normal mean is shown, **hetero normal range is 5–100 nmol/h/mg, ***normal range is 49.6–116 nmol/h/mg. ANA, antinuclear antibody, ND: not
determined, GPA: granulomatosis with polyangiitis, PSL: prednisolone, IVCY: intravenous cyclophosphamide, CYC: oral cyclophosphamide, HD: hemodialysis, αGL-A:
α-galactosidase A.
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onstrated IgG-positive and C3-positive immune deposits
along the capillary wall. Serum Cr was increased in the 3
previous cases (1.4–4.7 mg/dl) but not in the present case
(0.9 mg/dl), and the amount of proteinuria in the present
case was relatively low (0.6–1.3 g/day). Only the present
case was serologically positive for PR3-ANCA and defini-
tively diagnosed as GPA. Low peripheral leukocyte αGL-A
activity was detected in all three males, but not in the het-
erozygous female. All four patients were treated with
high-dosage prednisolone, and cyclophosphamide was
added in three cases. No deaths have been reported and
relatively benign courses in short observation periods have
been reported. Because renal pathological findings, includ-
ing the coexistence of granulomatous tubulointerstitial
nephritis, were not shown in detail and a survey of the
upper and lower respiratory tracts was not done in the
three previous cases, the coincidence of subclinical GPA
cannot be precisely confirmed.
The pathogenic relationship between Fabry’s disease
and GPA remains unknown. Galactocerebroside that ac-
cumulates in Fabry’s disease may be immunogenic [11],
leading to the emergence of immune-mediated disease
processes. Recently, Lin et al. demonstrated that neutro-
phil apoptosis in acute lung injury is inhibited via
sphingolipid signaling [12]. Neutrophils play the primary
pathogenic role in GPA [13-15]. Priming by proinflam-
matory cytokines causes translocation of ANCA antigensfrom the lysosomal compartments of neutrophils to the cell
surface during the early phase of the inflammatory process.
Engagement of ANCA with their antigens on the cell sur-
face and interaction of the Fc part of the antibody with Fc
receptors activate the neutrophils. Activated neutrophils ad-
here to vessel walls, produce reactive oxygen radicals, and
release lysosomal enzymes, ultimately resulting in necrotiz-
ing vascular injury. Accumulated glycosphingolipid may
provide long-term survival for neutrophils and contribute
to their sustained activation, exacerbating vascular injury.
Recently, a renal variant of Fabry’s disease that solely af-
fects kidneys was recognized in hemodialysis patients [16].
Nakao et al. reported that 6 (1.2%) out of 514 hemodialysis
patients had low plasma αGL-A activity. This finding sug-
gests that Fabry’s disease may be underdiagnosed in gen-
eral and may occur more often than expected in patients
with GPA or crescentic glomerulonephritis. Low αGL-A
activity may not result from an inherited genetic mutation;
it may reflect individual variation in its production or
regulation. Further studies will be required to investigate
the pathogenic link between the two diseases.
Conclusions
We describe a case in which Fabry’s disease and granulo-
matosis with polyangiitis occurred together, and discuss
three additional cases in which Fabry’s disease has been
reported to be concomitant crescentic glomeruloneph-
ritis. The remarkable concurrence of these disorders in
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share a pathogenic link. The information presented in
this report suggest that Fabry’s disease may, in fact, be
underdiagnosed, particularly in cases of GPA or cres-
centic glomerulonephritis.
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